Clinical Study Results
How many participants had serious adverse reactions?
There were 3.2% of participants who had serious adverse reactions during the whole
52 weeks of the study. This was 26 out of 813 participants. Participants who took
5 mg of dapagliflozin with insulin had more serious adverse reactions than
participants who took 10 mg of dapagliflozin with insulin. Participants who took
10 mg of dapagliflozin with insulin had a similar number of serious adverse reactions
as participants who took the placebo with insulin.
The most common serious adverse reaction during the study was increased
blood acids due to diabetes called diabetic ketoacidosis, also called DKA.
This happened in 1.8% of participants. This was 15 out of 813 participants.
Participants who took 5 mg of dapagliflozin with insulin had a similar number of
events of DKA as participants who took 10 mg of dapagliflozin with insulin.
One participant died during the study. This death was not related to the study drug.
How many participants had adverse reactions?
There were 27.1% of participants who had adverse reactions during the whole
52 weeks of the study. This was 220 out of 813 participants.
Participants who took 5 mg of dapagliflozin with insulin had a similar number of
adverse reactions as participants who took 10 mg of dapagliflozin with insulin.
Participants who took dapagliflozin with insulin had more adverse reactions than
participants who took the placebo with insulin.
What adverse reactions did the participants have?
In this study, the most common adverse reaction was frequent urination during
the daytime. This adverse reaction happened more in participants who took 5 mg
of dapagliflozin with insulin than in participants who took 10 mg of dapagliflozin
with insulin. This adverse reaction happened more in participants who took
dapagliflozin with insulin than in participants who took the placebo with insulin.
7